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CHRONIC VENOUS INSUFFICIENCY AND BIOPROSTHETIC
BICUSPID SQUARE STENT BASED VENOUS VALVE
FOR TRANSCATHETER PLACEMENT
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SUMMARY ∑ The past 25 years have witnessed experimental efforts at catheter-based manage-
ment of aortic, pulmonary and venous valve regurgitation. This chapter describes the initial designs
and experimental evolution of a bioprosthetic venous valve that can be implanted by using a
transcatheter technique. An evaluation of a percutaneously placed bioprosthetic, bicuspid venous valve
(BBVV) consisting of a square stent and small intestinal submucosa (SIS) covering was performed in
15 sheep. Of  30 BBVVs placed into the jugular veins, 28 exhibited good valve function on immedi-
ate venograms, and 25 on venograms prior to sacrifice. Gross and histologic examinations demon-
strated incorporation of remodeled and endothelialized SIS BBVVs into the vein wall. Minimally
invasive placed square stent based SIS valve is a promising one-way, competent valve.
Venous stasis or chronic venous insufficiency is the
result of valvular reflux, obstruction or both. Reflux in the
venous system is due to incompetent or destroyed valves.
Primary valvular incompetence (PVI) is the result of a
dilated valvular ring, redundancy or dysplasia of the valve
leaflets. In PVI, valves have smooth, thin wavy leaflets in
contrast to the thickened, deformed valve cusps associated
with secondary valvular insufficiency (SVI). SVI is asso-
ciated with a history of post-thrombotic event in etiology;
valve dysfunction causing stasis may also be a predispos-
ing factor to thrombosis1.
Chronic venous insufficiency (CVI) is a clinical con-
dition characterized by lower extremity venous hyperten-
sion2. Normal valve function and structure, combined with
foot and muscle pump action, comprise a complex hemo-
dynamic system required for efficient venous emptying of
calf veins in the upright position. William Harvey initially
evaluated the function of  venous valves in 16283, how-
ever, more than 300 years had passed before Eiseman and
Malette4 reported their experimental attempt at venous
valve repair. Then, 25 years ago, Kistner5 first described
venous valve repair in human beings. Internal valvulo-
plasty results for carefully selected patients with PVI show
70%-80% of good long term clinical  and duplex follow-
up, however, only 37%-100% of valve transplantation and
17%-66% of transposition procedures for CVI have good
long term patency6.
The challenge of correcting valvular incompetence has
recently included application of endovascular technique.
Newer approaches to restoration of valve competence in-
clude implantation of axillary vein valves or cryopreserved
valves and experimental work with canine jugular vein-
stent and cryopreserved vein stent combinations7.
A percutaneous, minimally invasive, outpatient treat-
ment of symptomatic reflux is an attractive concept. In
1981, Charles Dotter8 suggested transcatheter venous
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valve placement: “Catheter based devices have met clini-
cal success in the closure of patent ductus arteriosus and
atrial septal defects. Why not catheter-placed prosthetic
valves?”  In  1993, Uflacker reported percutaneous place-
ment in the inferior vena cava of pigs of a monocusp
venous valve consisting of a single body Z stent with
polyetherurethane or polytetrafluoroethylene (PTFE)
membrane9. Two more recent experimental studies have
employed catheter insertion of bovine jugular venous
valves mounted within an expandable stent10,11. Thorpe
at al. have also described promising short-term experi-
mental results with catheter insertion of a bicuspid venous
valve made from the porcine small intestinal submucosa
(SIS) mounted on a single body Z stent base12.
In 2000, Bonhoeffer et al.13 reported first successful
percutaneous valve replacement in a failed conduit from
the right ventricle to the pulmonary artery in a 12-year-
old boy. They used bovine jugular vein valve mounted
inside stent.
Square stent based venous valve
Recently, Pavcnik et al. have reported results of long-
term experimental study that are encouraging for the clini-
cal application of manufactured square stent venous valve
(Fig. 1). The square stent venous valves appear to undergo
remodeling with recipient’s own cells and function with-
out the need for anticoagulants. Therefore they have the
potential to treat chronic venous insufficiency by replac-
ing valves that are destroyed from thrombophlebitis or
that are incompetent14-16.
After deployment, the square stent based valve self-
expanded and appeared to function in the same manner
as a natural venous valve. The bioprosthetic bicuspid
venous valve (BBVV) was open during continuous
antegrade flow. When retrograde pressure was applied, the
BBVVs closed, and the two SIS leaflets sealed against
each other preventing retrograde flow through the valve
(Fig. 2).  BBVVs placed into jugular veins centrally (closer
to heart) or across the native valve (NV) took over the
function of these valves. All 16 BBVVs placed across the
NVs were functional with minimally thickened leaflets
after one, three and six months (Fig. 3). Twelve BBVVs
placed centrally to the NV had leaflets thickened to a
mean of 750 µ. This suggests that when replacing the
function of the natural valve in their location, BBVVs have
best chance to function.
A manufactured, percutaneously implantable, non-
immunogenic venous valve that remains patent and com-
petent over time is an attractive alternative to direct venous
valvular reconstruction or transplantation. The combina-
tion of a square stent and the biomaterial SIS14-16. permits
manufacture of a bicuspid venous valve that is anatomically
and functionally similar to the NV. Attached to a square
stent, SIS provides an effective bioscaffold for attraction of
host cells. The BVV incorporated into a vein wall consists
of two cusps, the valvular agger and the valvular sinus (Fig.
4). The cusp consists of a free border (SIS) and parietal part
(vein wall). The SIS used in these experiments was 120 to
180 ì thick and was approximately 4 and 6 times thicker
than the NV (30 µ)16.
At the BBVV agger, where the SIS leaflets were at-
tached to the vein wall, the SIS membranes were thick-
Fig. 1 Square stent based SIS venous valve.  A)  Non-restricted square stent based valve 20 mm long with 4 barbs for vein 14-15 mm in
diameter. A retention wire pusher connected to one barb retains valve. B)  Valve front loaded into a 9 Fr guiding catheter.
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Fig. 2 Function of the square stent based SIS venous valve placed into both external jugular veins. A) Jugular venogram with injection
distal to the valve demonstrates valve patency. This is analogous to the animal standing upright. B) High volume injection central to the
valve demonstrates closure of the valve with no leak. Valves must function in this manner to prevent cephalic reflux when the animal low-
ers its head to eat or drink.
ened. This chronic inflammation and cellular ingrowth
around sutures and the stent wires created a seal between
the vein wall and the two valve pockets15,16.  Parietal bor-
ders of BVV sinuses consisted of natural vein wall with
intact endothelium preventing local thrombosis (Fig. 3).
Out of 30 BVVs with 60 cusps, only one pocket of a single
misaligned BVV thrombosed. This suggests the SIS valve
is resistant to thrombosis. Venous endothelial cells were
attached to SIS one month after implantation. As this
process continued, other cells infiltrated the SIS, and the
ingrowth of host cells allowed for incorporation of the
valve and its borders into the vein wall16.
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The BBVVs described herein demonstrate several ad-
vantages over other prosthetic venous valves9-13. These in-
clude simple introduction with valve self-expansion and
self-attachment by barbs to the vein wall. The valve appears
stable and does not spontaneously migrate. The 9 Fr size
of the delivery catheter for BVV is smaller than that for
delivery of a monocusp valve9.   It is, however, much smaller
than the 16 Fr size for the bicuspid SIS covered Z stent
valve12 and the 18 Fr size required for insertion of a stent
mounted bovine jugular vein valve10,11,13. Another advan-
tage of the square stent based SIS valve is its availability in
different size for various vein diameters. They may also not
require anticoagulation. The results of this study are encour-
aging and warrant an experimental trial in humans15,16.
Fig. 3 Square stent based SIS valve 3 months after implantation in animal.  A)  Axial view from above shows incorporation of the bicuspid
valve into vein wall. B) Longitudinal microscopic view of both SIS leaflets. C)  High magnification of the SIS leaflet shows that the mem-
brane has been fully penetrated and reorganized by host cells, including fibrocytes, plasma cells, lymphocytes and endothelial cells. (Hema-
toxylin & eosin stain original magnification 400 x).
Fig. 4 Square stent based SIS valve at 6 months.  A) longitudinal cross-section shows an incorporated valve with two cusps and two si-
nuses. B) Longitudinal microscopic view of both remodeled SIS leaflets.
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Saæetak
KRONI»NA VENSKA INSUFICIJENCIJA I TRANSKATETERSKO POSTAVLJANJE BIOPROTETSKE
BIKUSPIDNE VENSKE VALVULE S »ETVEROKUTNIM STENTOM
D. Pavcnik
Proteklih 25 godina bili smo svjedoci eksperimentalnih pokuπaja u lijeËenju aortne i pulmonalne regurgitacije te insuficijencije
venskih zalistaka pomoæu katetera. U ovom Ëlanku opisuju se poËetne zamisli i eksperimentalni razvoj bioprotetskih venskih
valvula koje se mogu ugraditi transkateterskom metodom. Procjena perkutano postavljene bioprotetske bikuspidne venske
valvule (BBVV), koja se sastoji od Ëetverokutnog stenta i pokrova submukoze tankog crijeva (SIS), uËinjena je na 15 ovaca.
Od 30 BBVV-a postavljenih u jugularnu venu 28 je imalo urednu funkciju na venogramima uËinjenima odmah poslije zahvata,
a 25 na venogramima uËinjenima prije ærtvovanja æivotinja. Makroskopska i histoloπka analiza pokazale su uklapanje remodeliranog
i endoteliziranog SIS-BBVV-a u vensku stijenku. Valvula koja sadræi Ëetverokutni stent i SIS, postavljena uz minimalnu
invazivnost, jednosmjerna je valvula od koje se moæe oËekivati uspjeπnost.
Although a great deal of work remains to be done,
these early results indicate that the development of a bio-
logical prosthetic, pulmonary and venous valve for
transcatheter placement is more than feasible.
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